KM
CLVS

Kalos Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Kalos Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,500
Closed -$21K – 134
2022
Q2 		$21K Hold
10,500
– – 0.03% 133
2022
Q1 		$21K Sell
10,500
-14,570
-58% -$28.6K 0.01% 173
2021
Q4 		$110K Buy
25,070
+2,070
+9% +$7.65K 0.03% 278
2021
Q3 		$101K Sell
23,000
-750
-3% -$3.61K 0.03% 280
2021
Q2 		$130K Hold
23,750
– – 0.05% 249
2021
Q1 		$155K Hold
23,750
– – 0.05% 274
2020
Q4 		$114K Sell
23,750
-500
-2% -$2.53K 0.05% 236
2020
Q3 		$141K Buy
24,250
+200
+0.8% +$1.2K 0.06% 212
2020
Q2 		$162K Buy
24,050
+5,500
+30% +$41.6K 0.07% 195
2020
Q1 		$119K Buy
18,550
+7,500
+68% +$60.2K 0.05% 185
2019
Q4 		$114K Buy
+11,050
New +$80.4K 0.04% 189

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kalos Management's CLVS Position: Q3 2022 in Review

Kalos Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 10,500 shares — an estimated $21K sold.

Kalos Management first reported a position in CLVS in Q4 2019 and held it in 11 quarters. The position peaked at $162K in Q2 2020. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Kalos Management reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Kalos Management sold 10,500 Clovis Oncology, Inc. shares in Q3 2022, an estimated $21K.
  • Kalos Management first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 11 quarters.
  • Kalos Management's Clovis Oncology, Inc. position peaked at $162K in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Kalos Management's 13F filing for Q3 2022, filed 21 Nov 2022.